|
|
Post by wyattdog on Sept 21, 2022 17:17:50 GMT -5
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference 5:00 PM ET, 09/21/2022 - GlobeNewswire DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022. The Company’s webcast presentation will be available for viewing at 9:00am ET on Wednesday, September 28, 2022, on the Company's website at Events & Presentations or investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay. Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com. |
|
|
|
Post by sla55 on Sept 21, 2022 17:20:13 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-fall-2022DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022. The Company’s webcast presentation will be available for viewing at 9:00am ET on Wednesday, September 28, 2022, on the Company's website at Events & Presentations or investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay. Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com.
|
|
|
|
Post by neil36 on Sept 28, 2022 7:31:45 GMT -5
|
|
|
|
Post by veritasfiliatemporis on Sept 28, 2022 8:42:52 GMT -5
Conference quite good, Mike very confident about the future of the company " next two to five years "
|
|
|
|
Post by neil36 on Sept 28, 2022 9:09:44 GMT -5
Conference quite good, Mike very confident about the future of the company " next two to five years " First comment in a long time regarding India and Brazil. He seemed confident that Brazil sales will resume, but he said it has come with lots of bureaucratic challenges. He also said the exchange rate isn't helping make it financially appealing for that market. I was surprised how upbeat he was about doctor responses to V-Go. He seemed very confident that those sales will grow and it gives reps more opportunity to pitch Afrezza to new offices. My biggest takeaway from the call was him saying his biggest responsibility is capital allocation. My take is that they worked hard to get in a solid financial position and they don't want to pour money into promotions for Afrezza until they have new clinical trial results to win doctors over. They will place "bets" on the future pipeline candidates, but I don't think they want to "bet" money on Afrezza until the odds are more in their favor (higher dosing label, some level of superiority data, approval for children, which will create life-long patients, etc.) Overall good call. |
|
|
|
Post by neil36 on Sept 28, 2022 9:51:52 GMT -5
Statement regarding V-Go: "So we previously had given guidance of $18 to $22 million in the first twelve months and I think we are on track to hit the higher end of that"
-----
So if current Symphony retail sales are $850,000-ish per week, that is $44 million a year. So if he think they are on track to book $22 million in revenue the first twelve months, would that mean V-Go margins approach 50%?
|
|
|
|
Post by neil36 on Sept 28, 2022 10:07:26 GMT -5
He removed any doubt about COPD trial. Very clear that it didn't work out and won't be coming back. On the other hand, he was very bullish on TETON trial and said that if that is successful, it will be the blockbuster for UTHR and "the big leg up" for Mannkind.
He said they could bring forward molecules that might generate $100 to $200 million, but he said they want to make sure Tyvaso DPI is successful in bringing in $300 to $500 million a year (it wasn't the clearest sentence, but that was my understanding of his message).
|
|
|
|
Post by cppoly on Sept 28, 2022 10:14:12 GMT -5
Mike also said he was happy with the recent rulings with UTHR. Why LQDA is still holding is beyond me.
|
|
|
|
Post by peppy on Sept 28, 2022 10:17:34 GMT -5
He removed any doubt about COPD trial. Very clear that it didn't work out and won't be coming back. On the other hand, he was very bullish on TETON trial and said that if that is successful, it will be the blockbuster for UTHR and "the big leg up" for Mannkind. He said they could bring forward molecules that might generate $100 to $200 million, but he said they want to make sure Tyvaso DPI is successful in bringing in $300 to $500 million a year (it wasn't the clearest sentence, but that was my understanding of his message). TETON is a Phase 3 program consisting of two Phase 3 studies of Tyvaso® in subjects with idiopathic pulmonary fibrosis (IPF). The first of these studies, TETON 1, is enrolling patients in the United States. The second of these studies, TETON 2, is in start-up mode and will enroll patients outside the United States. In both cases, the primary endpoint is the change from baseline to week 52 in absolute forced vital capacity (FVC). Both the FDA and the European Medicines Agency have granted orphan designation for treprostinil to treat IPF. ~100,000 Patients pipeline.unither.com/product/teton-inhaled-treprostinil/description/ |
|
|
|
Post by mango on Sept 28, 2022 12:59:26 GMT -5
Statement regarding V-Go: "So we previously had given guidance of $18 to $22 million in the first twelve months and I think we are on track to hit the higher end of that" ----- So if current Symphony retail sales are $850,000-ish per week, that is $44 million a year. So if he think they are on track to book $22 million in revenue the first twelve months, would that mean V-Go margins approach 50%? Will we make back our original investment within 12 months? I remember awesomo arguing that would never happen.. Just curious if that is feasible with 22+ million in sales within first 12 months? |
|
|
|
Post by mango on Sept 28, 2022 13:02:31 GMT -5
He removed any doubt about COPD trial. Very clear that it didn't work out and won't be coming back. On the other hand, he was very bullish on TETON trial and said that if that is successful, it will be the blockbuster for UTHR and "the big leg up" for Mannkind. He said they could bring forward molecules that might generate $100 to $200 million, but he said they want to make sure Tyvaso DPI is successful in bringing in $300 to $500 million a year (it wasn't the clearest sentence, but that was my understanding of his message). $500 million was the estimate when they were including COPD-PH I believe. If that’s still a potential target amount that would be awesome but even $300+ million a year in royalties is game changing for us. Did Mike mention AG? Peds trial or any of the Phase 4 trials? Anything about clofazimine? |
|
|
|
Post by oldfishtowner on Sept 28, 2022 18:26:01 GMT -5
He removed any doubt about COPD trial. Very clear that it didn't work out and won't be coming back. On the other hand, he was very bullish on TETON trial and said that if that is successful, it will be the blockbuster for UTHR and "the big leg up" for Mannkind. He said they could bring forward molecules that might generate $100 to $200 million, but he said they want to make sure Tyvaso DPI is successful in bringing in $300 to $500 million a year (it wasn't the clearest sentence, but that was my understanding of his message). $500 million was the estimate when they were including COPD-PH I believe. If that’s still a potential target amount that would be awesome but even $300+ million a year in royalties is game changing for us. Did Mike mention AG? Peds trial or any of the Phase 4 trials? Anything about clofazimine? The $300-$500 million was not in reference to Tyvaso. The reference to Tyvaso was the first they had to make sure Tyvaso is a blockbuster drug.
In the discussion of the possibility of developing another molecule for UTHR Castagna mention a couple of possibilities they had looked at, but said they were not interested in co-developing a drug that only brought in $100-$200 million (presumably in revenue for UTHR) but they were looking for drugs that would bring in $300-$500 million and have a significant impact for patients. In other words, they are thinking big not small. I guess that the implication was that it might take them a bit more time to identify the next candidate, of course after Tyvaso was well on its way.
|
|
|
|
Post by awesomo on Sept 28, 2022 18:50:16 GMT -5
Statement regarding V-Go: "So we previously had given guidance of $18 to $22 million in the first twelve months and I think we are on track to hit the higher end of that" ----- So if current Symphony retail sales are $850,000-ish per week, that is $44 million a year. So if he think they are on track to book $22 million in revenue the first twelve months, would that mean V-Go margins approach 50%? Will we make back our original investment within 12 months? I remember awesomo arguing that would never happen.. Just curious if that is feasible with 22+ million in sales within first 12 months? The answer is no. Last quarter: V-Go net revenue: $2.1M V-Go gross profit: $0.9M So V-Go's gross margin was 38%... 38% of $22M (the absolute top end of guidance) is 8.36M which is less than the acquisition price of $10M. Oh, and none of this even accounts for sales/marketing/administrative expenses. |
|
|
|
Post by sportsrancho on Sept 28, 2022 22:28:13 GMT -5
Thanks so much Neil for all this❣️
|
|
|
|
Post by cedafuntennis on Sept 29, 2022 6:57:31 GMT -5
Your analysis omits the fact that the margin now will not include production and COGS as the deal included inventory per MC.
|
|
